Within-visit blood pressure variability and cardiovascular risk factors in hypertensive patients with non-dialysis chronic kidney disease.

CONCLUSIONS: We show that within-visit BP variability may be a clinically relevant factor of CVD risk, and lipid lowering and/or anti-hypertensive therapies using RAS inhibitors and α1-blockers may be associated with the improved within-visit BP variability observed in non-dialysis CKD patients.
PMID: 28635327 [PubMed - as supplied by publisher]

Source: Clinical and Experimental Hypertension - June 21, 2017 Category: Cardiology Authors: Azushima K, Wakui H, Uneda K, Haku S, Kobayashi R, Ohki K, Kinguchi S, Haruhara K, Fujikawa T, Toya Y, Umemura S, Tamura K Tags: Clin Exp Hypertens Source Type: research